Table 5.
Immunotherapies Currently in Phase 3 Development for Advanced Melanoma
Company | Product | Type |
---|---|---|
Vical/AnGes MG | Allovectin-7 | Allogeneic, plasmid DNA/lipid complex |
GlaxoSmithKline | MAGE-A3 ASCI | Allogeneic, peptide |
Avax Technologies | M-Vax | Autologous, whole-cell, hapten-modified |
Amgen (through acquisition of BioVex Group) | T-VEC (formerly OncovexGM-CSF; talimogene laherparepvec) | Allogeneic, oncolytic herpes simplex virus encoding GM–CSF |